New Drug Approvals

Home » Posts tagged 'Mumbai'

Tag Archives: Mumbai


Blog Stats

  • 4,123,798 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,772 other subscribers
Follow New Drug Approvals on



Recent Posts

Flag Counter


Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,772 other subscribers


DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK LIFE SCIENCES LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 PLUS year tenure till date June 2021, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 90 Lakh plus views on dozen plus blogs, 233 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 33 lakh plus views on New Drug Approvals Blog in 233 countries...... , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

Verified Services

View Full Profile →



Flag Counter

Anthony Crasto conferred ABPnews award for “Outstanding contribution to Education Sector”

DSC00403 Conferred prestigious award at event ABP News Presents Healthcare Leadership Awards 26th November, 2018 at Taj Lands End, Mumbai India
Dedicated to Shobha Crasto​ Aishal crasto Lionel crasto
Service to education is service to humanity
Society recognises efforts done towards it

47008795_2403920969650620_7189873006959656960_n 47115866_2405353396174044_6443851833482936320_nDSC00394

/////////////award,  event ABP News, Healthcare, Leadership,  26th, November, 2018, Taj Lands End, Mumbai,  India, education, anthony crasto

National award to Anthony Melvin Crasto for contribution to Pharma society from Times Network for Excellence in HEALTHCARE) | 5th July, 2018 | Taj Lands End, Mumbai, India

times now 1

DR ANTHONY MEVIN CRASTO Conferred prestigious individual national award at function for contribution to Pharma society from Times Network, National Awards for Marketing Excellence ( For Excellence in HEALTHCARE) | 5th July, 2018 | Taj Lands End, Mumbai India

times now 5


times 4







////////////National award,  contribution to Pharma society, Times Network, Excellence in HEALTHCARE,  5th July, 2018, Taj Lands End, Mumbai,  India, ANTHONY CRASTO


CHIRAL INDIA 2016, 5th International Conference & Exhibition Nov 8-9 2016, Holiday Inn, Mumbai, India



India's only conference focusing on new chiral technologies for pharmaceutical fine chemicals. The event is a unique platform to learn about recent advances in chiral chemistry, technology and application.

Chiral India series which began in 2012 has now grown into a major must-attend event for the Pharmaceutical industry. This platform is the most popular chiral technology platform bringing together the top experts from China, Canada, USA, Japan, India and other countries to present the latest developments in chiral drug developments and brainstorm with leading R&D personnel from Indian pharmaceutical industry.

The fifth edition of Chiral India to be held on 8-9 November 2016, at Holiday Inn (Mumbai), follows the success of previous four annual editions (2012, 2013, 2014 and 2015) and is now an event awaited by R&D professionals across the industry.

International panel of Chiral experts will address on key Themes
  • Asymmetric hydrogenations: New directions
  • Chiral switches: Development of single enantiomer drugs
  • Chiral tool kit in new drug development
  • Organo molecular catalysts
  • Enzymatic processes for new chiral drug synthesis
  • Chiral chemistry in natural product synthesis
  • Chiral catalysis: An overview of recent advances
  • Chiral drugs: New regulatory directions
  • Chiral separation technologies
  • Flow reactions for chiral drug development

R  Rajagopal

+9198211 28341

Dr. R. Rajagopal B-602, Godrej Coliseum Tel: +91 22 24044477
Editorial Advisor K.J. Somaiya Hospital Road Fax: +91 22 24044450
Chemical Weekly Sion (East) Mumbai 400 022


Please use link to download the Brochure.

Our website URL is


Oganised By






////////CHIRAL INDIA 2016, 5th International Conference, Exhibition,  Nov 8-9,  2016, Holiday Inn, Mumbai, India

P7435 from Piramal Enterprises Mumbai, India




Piramal Enterprises Mumbai, India

P-7435; P7435-DGAT1, P7435, P 7435

CAS 1210756-48-1,
C22 H19 F N4 O4 S
L-​Valine, N-​[[3-​[4-​[(6-​fluoro-​2-​benzothiazolyl)​amino]​phenyl]​-​5-​isoxazolyl]​carbonyl]​-
Molecular Weight, 454.47

GDAT1 inhibitor

  • Phase IDiabetes mellitus; Lipid metabolism disorders
  • ClassAntihyperglycaemics; Antihyperlipidaemics; Small molecules
  • Mechanism of ActionDiacylglycerol O acyltransferase inhibitors
Company Piramal Enterprises Ltd.
Description Diacylglycerol O-acyltransferase-1 (DGAT1) inhibitor
Molecular Target Diacylglycerol O-acyltransferase-1 (DGAT1)
Mechanism of Action Diacylglycerol O-acyltransferase-1 (DGAT1) inhibitor
Therapeutic Modality
Latest Stage of Development Phase I
Standard Indication Metabolic (unspecified)
Indication Details Treat metabolic disorders

  • 24 Nov 2014Piramal Enterprises completes a phase I trial in healthy, overweight or obese subjects in USA (NCT01910571)
  • 17 Jun 2014Adverse events and pharmacokinetics data from a phase I trial in healthy male volunteers presented at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA-2014)
  • 17 Jun 2014Pharmacodynamics data from preclinical studies in Dyslipidaemia and obesity presented at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA-2014)

Chairman Ajay Piramal

Swati Piramal-The Vice Chairperson of Piramal Enterprises Ltd

Nandini Piramal, Executive Director, Piramal Enterprises

Piramal Enterprises gets US FDA approval for P7435 IND

Our Bureau, Mumbai
Tuesday, August 06, 2013, 12:25 Hrs  [IST]

Piramal Enterprises Ltd has received US Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) P7435. This is a novel, potent and highly selective, oral diacylglycerolacyltransferase 1 (DGAT1) inhibitor.

P7435 has been developed by the NCE Research Division of PEL for the management of metabolic disorders such as lipid abnormalities and diabetes. It is well-established that increased lipid levels’ (including triglycerides) is one of the major risk factors for cardiovascular disease (CVD). It has been reported by the World Health Organisation, that CVD, is the number one cause of deaths globally, representing approximately 30 per cent of all deaths. Currently, there is a significant medical need for effective and safe drugs for the management of lipid abnormalities and metabolic disorders.

P7435 has demonstrated its lipid lowering potential in various preclinical studies by showing significant reduction in triglyceride levels, glucose and insulin levels,and decrease in food intake and body weight gain -factors which are associated with lipid abnormalities and metabolic disorders.

PEL has established the safety and tolerability of P7435 in a phase I trial recently completed in India. This extension trial in the US will further evaluate the safety and efficacy of P7435 in a larger population.

Dr Swati Piramal, vice chairperson, Piramal Enterprises, said, “The NCE Research division of PEL continues its ambitious diabetes/metabolic disorders programme to discover and develop NCEs to fight against diseases like diabetes and lipid disorders. With P7435 we are looking at addressing a serious need for effective and well-tolerated drugs that treat lipid disorders, which are commonly associated with diabetes and CVDs. Expansion of this trial will allow testing this NCE in a wider population,which is critical to the development of this drug and will provide therapeutic solutions not just to India but also to the rest of the world.”

The NCE Research division of Piramal Enterprises focuses on the discovery and development of innovative small molecule medicines to improve the lives of patients suffering from cancer, metabolic disorders and inflammatory conditions. The key elements of its strategy include capitalizing on Piramal’s strengths, in particular the India advantage, and leveraging external partnerships to achieve high levels of R&D productivity. Piramal’s state-of-the-art Research Centre in Mumbai has comprehensive capabilities spanning target identification all the way through clinical development. Its robust pipeline, including 8 compounds in clinical development, bears testimony to its innovative and rigorous drug discovery process.


European Journal of Medicinal Chemistry (2012), 54, 324-342


WO 2010023609

/////////Piramal Enterprises,  Mumbai, India, P-7435, P7435-DGAT1, P7435, P 7435, GDAT1 inhibitor


Flow Chemistry India 2016, 21-22 January 2016, Mumbai, India

Flow Chemistry India 2016

Date: Thursday, 21 January 2016 Friday, 22 January 2016
Location: Mumbai, India




Hotel Ramada Powai and Convention Centre, Mumbai, India

Paul Watts

Professor & Research Chair, Nelson Mandela Metropolitan University

Shu Kobayashi

Professor, Synthetic Organic Chemistry , The University of Tokyo

Vivek Ranade

Deputy Director and Chair, National Chemical Laboratory

Volker Hessel

Professor, Eindhoven University of Technology

Claude de Bellefon

Scientific Director, University of Lyon

Ferenc Darvas

Chairman, Flow Chemistry Society

Marek Trojanowicz

Professor, University of Warsaw




Pooja Sharma and Sakshi Modgil,


Garima Sharma

 Maninderjit Singh Ahluwalia


SELECTBIO INDIA is delighted to welcome you all at the 4th International Conference Flow Chemistry India 2016 to be held in Mumbai on January 21-22, 2016 under the auspices of the Flow Chemistry Society.  The society aims to unite and represent those who are actively working on this rapidly developing field. This meeting is dedicated to the integration of flow chemistry into everyday practice throughout the world by delivering the latest knowledge and making it available for the entire chemistry community.

Society members save 25% on the registration fee and non-members will receive their first year’s membership included in the fee.

Running alongside the conference will be an exhibition covering the latest technological advances in the area of flow chemistry.

Who Should Attend

• Scientists, Chemists, Chemical Engineers and Researchers working in Pharmaceutical and Fine Chemicals Research and Development including Drug Discovery, Medicinal Chemistry and Chemical Process Development

• Scientists, Chemists and Chemical Engineers working in Pharmaceutical and Fine Chemical Bulk Manufacturing Units

• Corporate Management, Scientists, Managers responsible for development of Pharmaceutical and Fine Chemicals R & D and Manufacturing activities

• Scientists, Chemists & Engineers belonging to the fields of Inorganic, Organic, Medicinal, Natural Products, Analytical, High-throughput and Process Chemistry in the Academic research as well as in Applied research and development in the area of Agrochemical, Petrochemical and Fragrance industry

• Scientists working in or interested in applications of Flow Chemistry in Material science, Green chemistry, Nanotechnology, Biotechnology, Theoretical Chemistry, Information technology and Flow synthesis instruments including Engineering & Automation

Conference Package – Includes Registration, 2 Nights Accommodation, Dinner & Airport Transfers (Valid up to January 5, 2016 only)

Call for Posters

You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!

Poster Submission Deadline: 30 November 2015

Agenda Topics

  • Advances in Micro & Continuous Flow Reactors, Systems & Processes
  • Applications in Pharmaceutical Industry & API Synthesis
  • Engineering Aspects of Flow Chemistry
  • Flow Reactor – Choosing the Right One
  • Photochemistry & Multistep Synthesis in Flow
  • Quality Issue and QbD in Flow Chemistry
  • Scale up – From Micro to Commercial Scale
  • Yield Improvement, Cost Cutting and Waste Reduction in Flow Chemistry

Sponsorship and Exhibition Opportunities

Maninderjit Singh, Exhibition Manager



Workshop Tutor

Charlotte Wiles


A Workshop on “Flow Chemistry Demonstrations (Lab & Plant Scale) for Chemical and Pharmaceutical Industry-” will be held one day prior to the training course i.e. on 20th January, 2016 from 10:00 am – 05:00 pm in Mumbai. This workshop is supported by Process Intensification will be jointly conducted by :

Dr. Dinesh Kudav (Mumbai University); Dr. Charlotte Wiles (Chemtrix BV-Neth);  Mr. Wouter Stam (Flowid, NV-Neth); Mr. Manjinder Singh (CIPLA & VP-FCS-India Chapter);  Dr. Viktor Gyollai, (AM Technology-UK);  Dr. Prashant Kini (UPL Ltd.); Mr. Kumar Oza (Pi & TCPL);  Mr. Madhav Sapre (Pi & Sharon Bio); et al .

This workshop is specially designed to demonstrate application/capabilities of  Flow Chemistry running “live” reactions in Continuous Flow Reactors. The reactions likely to be demonstrated using Flow Chemistry includes :• Nitration • Organometallic reaction• Oxidation • Bi-phasic reaction• Nano-Particle preparation in Flow• Biocatalytic Reaction with enhanced enzyme life.

This workshop is free for the registered delegates of Flow Chemistry India 2016 Conference and Continuous Flow Reactors Training Course.

You can visit Mumbai city

Taj hotel, mumbai

Gateway of india

Food in mumbai

mumbai skyline

The Bandra-Worli Sea Link is a cable-stayed bridge that connects central Mumbai with its western suburbs



 get in if you can

 The Mumbai Suburban Railway system carries more than 6.99 million commuters on a daily basis. It has the highest passenger densities of any urban railway …



Chhatrapati shivaji in mumbai india

British-victoria terminus




Indian pharma’s struggle to tighten standards paves way for M&A deals

Indian pharma's struggle to tighten standards paves way for M&A deals
People walk past a chemist shop at a market in Mumbai. Photo: Reuters

MUMBAI – India’s smaller generic drugmakers, struggling to cope with a bruised reputation and tougher regulation in the United States, are under pressure to consider branching out to new, less-profitable markets or sell out to larger rivals.

Two years after its most high-profile regulatory setback to date in the United States – Ranbaxy’s $500 million U.S. fine for drug safety violations – India’s $15 billion a year generic drug industry is still rebuilding its image in its biggest market.

Many of its top firms are facing sanctions at some of their factories, as the U.S. Food and Drug Administration (FDA) tightens checks and its approvals process.

Combined with government-mandated price controls on drugs at home, that is piling pressure on smaller players.

“If they want to have a presence globally, they have to make investments. If they can’t, then they’ll have to focus on other markets or scale back their ambition outside of India, and that’s probably what will happen,” said Subhanu Saxena, CEO of Cipla , India’s fourth-largest drugmaker by revenue.

Ashok Anand, president of Hikal Ltd , a Mumbai-based drugmaker with a market value of $167 million, said some peers were putting themselves on the block.

“If they cannot deal with the stricter regulations, they might just prefer to sell out,” he said.

Pressure on U.S. sales has been felt across the Indian industry, with all drugmakers hit by delays in FDA approvals as the U.S. safety body overhauls its review process. Growth in U.S. revenue for drugmakers slowed to 14 percent in the year to March 2015, less than half what it was in the year to March 2012, according to brokerage Edelweiss.

Flexible exit, limited cost mooted for financial products to curb mis-selling - Economic Times

But for larger players who want to plug gaps or, for the likes of Glenmark and Aurobindo who aim to grow in the United States, this pressure has lowered prices and could pave the way for attractive deals, bankers said.

“Now that some of the smaller companies are reeling under intensive regulatory scrutiny and want to cash out on their investments, valuations would be much more realistic,” said the head of India M&A at a large European bank in Mumbai.


Indian manufacturers say they have spent millions in high-end testing equipment, improved training and have hired larger teams in quality control since Ranbaxy was fined for manipulating clinical data.

Some consultants estimate spending on compliance has more than doubled to reach about 6 to 7 percent of sales for the larger companies.

But while the number of U.S. export bans issued to Indian companies fell to eight in 2014 from 21 in 2013, according to FDA data, the agency continues to find manufacturing violations at the plants of some of the biggest drugmakers in the country, an indication of the pervasiveness of the problem.

Sun Pharmaceutical Industries , Wockhardt , Dr Reddy’s Laboratories and Cadila Healthcarehave all faced FDA rebukes over the past year.

Smaller firms Ipca and Aarti Drugs faced FDA bans on their plants this year.

These failures – which executives blame on India’s “quick fix” culture and consultants blame on a failure to prioritize compliance – have clouded short-term growth prospects and added to pressure on smaller players, pushing some to look elsewhere.

“They can choose to be in lesser-regulated markets, such as Latin America, where there is a lot of demand. But they will have to live with much thinner margins,” said the finance director of a small Indian drugmaker, who did not want to be named. “It’s survival of the fittest.” REUTERS



Pi-Process Intensification Experts LLP at CPhI Mumbai India 3rd Dec 2014…My visit


I (Dr Anthony) seated with Dr Vijay Kirpalani CEO of Pi-Process Intensification Experts LLP
at CPhI Mumbai India 3rd Dec 2014
Pi-Process Intensification Experts LLP

Process Intensification

Creating competitive advantage through Improved and consistent quality, high efficiencies and maximum flexibility.

Safer, Cleaner, Smaller, Cheaper and Smarter processes , The basic principle of Process Intensification is to fit the equipment to the process and not process to the equipment, as is the case now.

Process Intensification can achieve drastic improvement in the time cycle and yields as well as converting batch processes to continuous process using specialized set of equipment. The design philosophy in process intensification is to design a process which has Chemical Kinetics as its only limitation. See the illustration below

“Process Intensification by Kinetics alone controlling the reaction, using specialized equipments; modification / telescoping of process steps achieves drastic reduction in time cycles and converts batch processes to continuous ; Reduced energy consumption, Reduced by-product formation; sustainability , hazard-containment, compliance to QbD and PAT and importantly a much faster time-to-market”

Illustrative examples are as follows:

  • Watt’s aldol reaction: Time needed to reach 100 % conversion 20 minutes against 24 hours in batch process
  • Fisher Esterification: Pi gives 83% yield against 15% in batch process
  • Grignard Reaction: Pi gives 78% yield against 49% in batch process
  • Nitration Reaction: Product purity increase from 56% to 78% and yield of mononitrate increases 55% to 75%.
Benefits of Process Intensification (PI) Techniques

Benefits of Process Intensification (PI) Techniques

Sponsored Projects

Scale-up for Retrofitting in existing plant as well as greenfield projects based on flow chemistry data generated in our laboratory. A well-equipped Laboratory and Pilot Plant set-up is available at our “Pi-Lab” for carrying out “FLOW Chemistry” based Reactions and utilizing numerous Process Intensification techniquesfor Unit-Processes & Unit-Operations for the industry to reap the benefits of Process Intensification.

The laboratory and pilot plant data will be utilized to provide the plant scale design using specialized equipments like micro-reactors, micro-plate-reactors in SiC, monolithic loop reactors, spinning disk reactors-cum-heat exchangers, FUMI reactors, dynamic mixing reactors, oscillatory baffled reactors (OBR), Bio-catalytic impregnated membrane Reactors, and other modern state-of-the-art equipments enabling conversion of batch to continuous flow processes.

We handle hazardous chemistries with very high exotherms (upto 1300 J/gm) safely in the range of -70oC to + 250oC with pressures upto 200 bar, and with reaction times from 0.03 sec to 1 hour and reactor volumes from 0.2 ml to 100 ml (Lab) and 1 L (Pilot) — yielding from 20 gms to 8 Kgs/hour (Lab) and 500 gms to 200 Kgs/hour (Pilot).

Scale Up – Flexibility & Adaptability

Pi …… will provide all the services for scale up to the sizes desired by clients by utilizing data from Laboratory trials.


A range of Flow Chemistry and Process Intensification equipments can be offered on rent. This enables the users to get the hands-on experience so as to select the apt equipments for their needs.

Vijay Kirpalani
Pi-Process Intensification Experts LLP
Plot-W-33,  M.I.D.C. Industrial Area
TALOJA – 410208, Navi Mumbai, INDIA
email :
Tel: +91-9321342022 // +91-9821342022

some pics from hall 5 -H-47 at cphi mumbai india dec 3 2014







Flow Chemistry test facility in India

Chemtrix-India Test Facility1

Flow Chemistry test facility in India


on  Plantrix® Industrial system.

Vijay Kirpalani
Vijay Kirpalani
0091 9821 3420 22

More information
Stan Hoeijmakers
0031 (0)46 70 22 600


Chemtrix at CPhI India
2 – 4 December 2014
Mumbai, India

Booth H47, Hall 5
Pi Process Intensification

read at


Plantrix® Industrial Flow Chemistry Test Facility in India
Header NEWSL.


on our Plantrix®
Industrial system.


Vijay Kirpalani
0091 9821 3420 22

More information
Stan Hoeijmakers
0031 (0)46 70 22 600


Chemtrix at CPhI India
2 – 4 December 2014
Mumbai, India

Booth H47, Hall 5
Pi Process Intensification

Plantrix® MR260 now available for demo’s and trial’s
Chemtrix BV and Pi Process Intensification are proud to announce the opening of our Plantrix® test facility in India. ‘This test facility in New-Mumbai allows our customers to try their reaction(s) of interest on our Plantrix® (SiC) Industrial Flow Chemistry systems’ comments Vijay Kirpalani of Pi Process Intensification. Plantrix® is the product range for Industrial Continuous Manufacturing of Chemtrix BV in the Netherlands. Please click here for more info on Plantrix®.

Plantrix 2

To learn more about Industrial Continuous Manufacturing, please click here for a white paper. In addition to providing an overview of commercial examples of industrial scale continuous manufacturing, this article focuses on the key points to consider when embarking on the development of a continuous process.

Usefull for Year-End Budgets

Stock lab systems for method development (Labtrix® Start and Labtrix® S1). If you would like to have more info on these systems, lead times and pricing, please contact us here.

           Labtrix® Start (manual)                               Labtrix® S1 (automated)

Tel: 0031 (0)46 70 22 600
Fax: 0031 (0)46 70 22 603



Chemtrix Bv.
Urmonderbaan 22
Geleen, 6167RD


%d bloggers like this: